Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 24: The SENIOR RITA Trial
Author(s): Vijay Kunadian Added: 8 months ago
ESC Congress 2024 — No difference in cardiovascular outcomes between invasive and conservative strategies in elderly NSTEMI patients.Principal Investigator, Prof Vijay Kunadian (Newcastle upon Tyne Hospitals NHS Trust, UK) join us in London to discuss the key findings from the SENIOR RITA trial (NCT03052036; Newcastle-upon-Tyne Hospitals NHS Trust).The SENIOR-RITA trial is a multicenter, open… View more

Demographic

Prevention & Chronic Conditions
Assessing Coronary Angiography Interpretation Education
Author(s): Kayla A Riggs , Jay Gopal , Carson Keck , et al Added: 3 months ago

Digital Health

Intervention
Invasive Evaluation for Coronary Vasospasm
Author(s): Jingwen Huang , Rebecca Steinberg , Matthew J Brown , et al Added: 1 year ago

MI/ACS

Intervention
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 1 month ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure
EHRA 25: The MORE-CRT MPP Trial
Author(s): Christophe Leclercq Added: 1 month ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire… View more

Electrophysiology & Arrhythmia
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 1 month ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
AHA 24 Late-Breaking Discussion: The ZODIAC Trial
Author(s): Harriette Van Spall , Kausik Ray Added: 6 months ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising… View more

Prevention & Chronic Conditions

MI/ACS
TCT 24: The TRISCEND II Trial
Author(s): Susheel Kodali Added: 6 months ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a… View more

Intervention
Chelation Therapy in Post-MI Pts with Diabetes: TACT2
Author(s): Gervasio L Lamas Added: 1 year ago
ACC 24 - In this video, Dr Gervasio L Lamas (Mount Sinai Medical Center, US) joins us onsite to discuss the findings from the TACT2 study of chelation therapy in post-myocardial infarction patients with diabetes (NCT02733185).The Trial to Assess Chelation Therapy 2 (TACT2) study is a randomized, double blind factorial clinical trial, aiming to determine if chelation-based strategy increases the… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Cardiotoxicity in Breast Cancer: Challenges of Multimodal Therapies
Author(s): Dan Lenihan , , , et al Start date: Jun 08, 2023
Cardiotoxicity in breast cancer has emerged as a significant concern due to the increasing use of multimodal therapies, which combine different treatment modalities such as chemotherapy, targeted therapies, and radiation. While these therapies have improved survival rates, they can also have detrimental effects on the heart, leading to cardiotoxicity. For the second edition of this series of… View more

CV Disease in Special Populations